Healthtech Solutions Inc. (HLTT) Broadens Portfolio with Acquisition of Varian Bio, Enters Precision Cancer Care Market
Healthtech Solutions is acquiring Varian Biopharmaceuticals, developer of atypical protein kinase C iota inhibitors within thriving precision oncology market Varian Bio is developing two pre-clinical experimental drugs, VAR-101 for basal cell carcinoma and VAR-102 for a variety of solid tumors, including pancreatic, colorectal and NSCLC. Varian Bio will join MediScan, RevHeart in Healthtech’s portfolio of innovative healthcare technology companies For more than three decades, scientists searched to find the connection between human cancers and the protein kinase C group with little success. Things changed around 2006 with the discovery of atypical protein kinase C iota (aPKC iota, or aPKCi), an…